<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of idiopathic pulmonary fibrosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of idiopathic pulmonary fibrosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of idiopathic pulmonary fibrosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Talmadge E King, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Idiopathic pulmonary fibrosis (IPF; also called cryptogenic fibrosing alveolitis) is specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring in adults and limited to the lungs. It is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP). In the past, treatment was aimed at minimizing inflammation and slowing the progression from inflammation to fibrosis. However, the underlying lesion in IPF may be more fibrotic than inflammatory, explaining why few patients respond to anti-inflammatory therapies and the prognosis remains poor [
         <a href="#rid1">
          1-4
         </a>
         ].
        </p>
        <p>
         The following questions will be discussed in this topic review, although considerable uncertainty remains about the answers [
         <a href="#rid2">
          2,4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Which patients should be treated?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When should therapy be started?
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         What is the best therapy?
        </p>
        <p>
        </p>
        <p>
         The pathogenesis, evaluation, diagnosis, monitoring, and prognosis of IPF are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4300.html" rel="external">
          "Pathogenesis of idiopathic pulmonary fibrosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology", section on 'Usual interstitial pneumonia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14870.html" rel="external">
          "Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113935.html" rel="external">
          "Prognosis and monitoring of idiopathic pulmonary fibrosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/110885.html" rel="external">
          "Acute exacerbations of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          NATURAL HISTORY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following observations about the natural history of IPF may be helpful in guiding therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Historically, untreated IPF progresses, although disease progression is usually insidious, at least initially [
         <a href="#rid5">
          5-7
         </a>
         ]. Data from the placebo arm of clinical trials suggest that the rate of decline in forced vital capacity (FVC) among untreated patients is 150 to 200 mL per year [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The course of the disease may be unpredictable as some patients develop an acute deterioration after a period of apparent stability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients in the age group affected by IPF (the majority are &gt;55 years old) may have difficulty discerning whether their functional limitations are the result of disease progression, deconditioning, or simply the aging process.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comorbid conditions (eg, chronic obstructive pulmonary disease [COPD], heart failure) may also contribute to symptoms such as cough and reduced exercise tolerance.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          GENERAL APPROACH
         </span>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most important first step is to establish the diagnosis since misdiagnosis can lead to inappropriate initial therapy  (
         <a class="graphic graphic_algorithm graphicRef69044" href="/z/d/graphic/69044.html" rel="external">
          algorithm 1
         </a>
         ). The diagnosis of IPF may be established with a high degree of confidence in patients with a compatible clinical presentation, typical high-resolution computed tomography (HRCT) findings (eg, subpleural, bibasilar predominance of reticular markings, honeycombing, and the absence of features inconsistent with usual interstitial pneumonia [UIP] pattern, eg, ground glass opacities, micronodules, cysts, or mosaic attenuation), and no evidence of another contributing process (eg, asbestos exposure, hypersensitivity pneumonitis, systemic sclerosis, rheumatoid arthritis) [
         <a href="#rid2">
          2
         </a>
         ]. Family history may identify cohorts at risk for familial UIP or other fibrosing lung diseases. The diagnosis of IPF is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14870.html" rel="external">
          "Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p>
         When the results of HRCT are not classic for IPF, a video-assisted thoracoscopic or surgical lung biopsy is often necessary. (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology", section on 'Usual interstitial pneumonia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
         The next step is to stage the patient's severity of disease as this will help to guide treatment choices. Finally, a disease management plan is tailored to the disease severity and desires of the individual patient. Management generally includes a combination of supportive care, use of selected medications (eg,
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         ), consideration for participation in clinical trials, referral for lung transplant evaluation (when appropriate), and identification and treatment of comorbidities [
         <a href="#rid2">
          2,4
         </a>
         ]. (See
         <a class="local">
          'Medical therapies'
         </a>
         below.)
        </p>
        <p>
         Education and various components of supportive care (eg, supplemental oxygen, pulmonary rehabilitation, preventive measures against lung injury, palliative care) should be offered to all patients with IPF. (See
         <a class="local">
          'Supportive care'
         </a>
         below.)
        </p>
        <p>
         Multiple therapies (eg, anticoagulation, azathioprine-prednisone-[N]
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          acetylcysteine
         </a>
         combination therapy,
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , endothelin receptor antagonists, interferon gamma,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , [N] acetylcysteine,
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          penicillamine
         </a>
         ) have been used in the past either in case series or clinical trials. The agents of doubtful benefit or intolerable toxicity are described below with the evidence against their routine use. (See
         <a class="local">
          'Therapies without clear benefit'
         </a>
         below.)
        </p>
        <p>
         Ongoing assessment is needed to refine these choices as the disease progresses. (See
         <a class="medical medical_review" href="/z/d/html/113935.html" rel="external">
          "Prognosis and monitoring of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Assessing disease severity and prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disease severity in IPF is assessed based on symptoms, HRCT, and pulmonary function testing. Patients usually progress from mild to moderate to severe respiratory limitation, although the rate of progression can vary over the course of the disease. The factors that influence prognosis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/113935.html" rel="external">
          "Prognosis and monitoring of idiopathic pulmonary fibrosis", section on 'Prognosis'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with mild or early disease are often asymptomatic or may have a mild, nonproductive cough and dyspnea with substantial exertion. Radiographic changes of reticular opacities and areas of honeycombing are limited to subpleural and basilar areas, involving less than 10 percent of the lung parenchyma. Pulmonary function tests may be normal or may show mild reductions in forced vital capacity (FVC), diffusing capacity (DLCO), and/or distance walked on the six-minute walk test. The alveolar to arterial oxygen gradient (P[A-a]O
         <sub>
          2
         </sub>
         ) is normal or mildly elevated (&lt;20 mmHg).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate disease is characterized by dyspnea on moderate exertion, nonproductive cough, and mild-to-moderate pulmonary function abnormalities. The last may include a reduced FVC (eg, 50 to 70 percent of predicted), a reduced DLCO (eg, 45 to 65 percent of predicted), and/or increased P(A-a)O
         <sub>
          2
         </sub>
         (eg, 21 to 30 mmHg). Discordance in the degree of impairment of FVC and DLCO may be noted. Supplemental oxygen may be needed with exertion. Radiographic changes are more extensive with reticular opacities involving 20 to 30 percent of the lung and honeycombing involving &lt;5 percent of the parenchyma [
         <a href="#rid9">
          9
         </a>
         ]. One way of assessing the extent of radiographic changes is to quantitate these radiographic abnormalities on HRCT slices taken at three levels (eg, tracheal carina, inferior pulmonary veins, and 1 cm above the dome of the diaphragm) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Advanced disease is characterized clinically by dyspnea on mild exertion (eg, walking &lt;300 feet or climbing more than one flight of stairs) and requirement for supplemental oxygen at rest and/or with exertion. Extensive honeycombing is noted on HRCT (&gt;5 percent of the parenchyma in three or more zones) [
         <a href="#rid9">
          9
         </a>
         ]. Pulmonary function testing typically reveals moderate to severe reductions in the FVC (&lt;50 percent of predicted), DLCO (&lt;50 percent of predicted), and oxygen desaturation (≥4 percent) during a six-minute walk test [
         <a href="#rid10">
          10
         </a>
         ]. Gas exchange is also impaired with room-air oxygen saturation below 88 percent and elevated P(A-a)O
         <sub>
          2
         </sub>
         difference (&gt;30 mmHg).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2857291914">
         <span class="h3">
          Gender-Age-Physiology (GAP) model
         </span>
         <span class="headingEndMark">
          —
         </span>
         When developing a treatment plan for each patient, it is helpful to have an estimate of prognosis. The most widely validated clinical prediction model is the GAP model, which incorporates age, gender, FVC, and DLCO into a simple point-score index and staging system predictive of one, two, and three-year mortality [
         <a href="#rid11">
          11
         </a>
         ]. The GAP index and staging system, combined with clinical impression, can be used to guide initial patient discussions regarding prognosis, therapeutic options, urgency of lung transplantation, and timeline of palliative approaches. The GAP system is described in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/113935.html" rel="external">
          "Prognosis and monitoring of idiopathic pulmonary fibrosis", section on 'Predictors of mortality'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Ongoing monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ongoing monitoring is used to evaluate the clinical course and identify patients with accelerated deterioration. The response to therapy is usually assessed at three- to six-month intervals. We monitor a combination of symptoms, pulmonary function, and exercise capacity as described separately. (See
         <a class="medical medical_review" href="/z/d/html/113935.html" rel="external">
          "Prognosis and monitoring of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p>
         In patients with advanced or progressive disease, careful evaluation for the development of hypoxemia, pulmonary hypertension, thromboembolic disease, or other comorbid conditions (eg, chronic obstructive pulmonary disease [COPD], heart failure, obstructive sleep apnea, depression) may yield additional treatment options [
         <a href="#rid2">
          2,12,13
         </a>
         ]. (See
         <a class="local">
          'Supplemental oxygen'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/8258.html" rel="external">
          "Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8253.html" rel="external">
          "Epidemiology and pathogenesis of acute pulmonary embolism in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults"
         </a>
         and
         <a class="local">
          'Lung transplantation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          SUPPORTIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most important components of supportive care for patients with IPF are provision of supplemental oxygen (when needed), education (including advice about smoking cessation), pulmonary rehabilitation, and vaccination against
         <em>
          Streptococcus pneumoniae
         </em>
         and influenza [
         <a href="#rid2">
          2,14
         </a>
         ]. Affective disorders are common during the course of IPF and may need attention [
         <a href="#rid15">
          15,16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14623.html" rel="external">
          "Comorbid anxiety and depression in adults: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Supplemental oxygen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Virtually all patients with IPF will eventually require supplemental oxygen initially just with exertion and then continuously. Oxygen therapy should be prescribed to enable maintenance of normal activity and possibly to prevent or delay the onset of secondary pulmonary hypertension in hypoxemic patients. The indications, benefits, and prescription of supplemental oxygen are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">
          "Long-term supplemental oxygen therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Education
         </span>
         <span class="headingEndMark">
          —
         </span>
         Results from a survey regarding patients' experience with IPF suggest that improved education and communication about the diagnosis and management of IPF are needed [
         <a href="#rid17">
          17
         </a>
         ]. For patients with progressive IPF, part of the education should include a discussion of end-of-life issues and advanced directives. Understanding a patient's individual preferences, beliefs, and values is a key step toward achieving an appropriate management plan [
         <a href="#rid18">
          18
         </a>
         ]. Introduction of principles of palliative care for patients with IPF should be undertaken in patients with progressive IPF. (See
         <a class="medical medical_review" href="/z/d/html/14240.html" rel="external">
          "Benefits, services, and models of subspecialty palliative care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14238.html" rel="external">
          "Assessment and management of dyspnea in palliative care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2200.html" rel="external">
          "Hospice: Philosophy of care and appropriate utilization in the United States"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Pulmonary rehabilitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most of the data that support the use of pulmonary rehabilitation in the management of patients with chronic respiratory disease come from the study of chronic obstructive pulmonary disease (COPD). Several studies also support the use of pulmonary rehabilitation in interstitial lung disease [
         <a href="#rid19">
          19-28
         </a>
         ]. As an example, in a series of 113 patients with interstitial lung disease, a significant reduction in dyspnea and improvement in six-minute walk distance were found following participation in a pulmonary rehabilitation program [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">
          "Pulmonary rehabilitation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Prevention of pulmonary infections and acute exacerbations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary infections are poorly tolerated in patients with IPF [
         <a href="#rid29">
          29,30
         </a>
         ]. In addition to the acute effect on lung function, pulmonary infection may result in an acute exacerbation of IPF (AE-IPF), which is defined as "an acute, clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality" [
         <a href="#rid31">
          31
         </a>
         ]. AE-IPF may result from direct lung injury due to chemical, mechanical, or autoimmune etiologies. Further details of risk factors, evaluation, diagnosis, and management of AE-IPF are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/110885.html" rel="external">
          "Acute exacerbations of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p>
         Given our limited understanding of the pathophysiology of acute exacerbations, the primary focus of prevention is avoidance of respiratory infections and other lung injury. In our practice, this typically includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaccination
         </strong>
         <strong>
          against respiratory infections
         </strong>
         , including:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          Streptococcus
         </em>
         <em>
          pneumoniae
         </em>
         , regardless of age, according to United States
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fvpd%2Fpneumo%2Fhcp%2Fwho-when-to-vaccinate.html&amp;token=L%2Bc8zr4d8P%2F6yQBHvQAQPmACJHX7X%2FYTa3xdsci3Hl8OHVV71Q4IIthzYiqHTWXTNgzqRUsLsdezDVio%2FXj9CiNgc639MRFzflgmY5ahvu4%3D&amp;TOPIC_ID=4328" target="_blank">
          Centers for Disease Control and Prevention (CDC) guidelines
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Influenza (yearly, as per the standard adult vaccination schedule)  (
         <a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">
          figure 1
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          Bordetella
         </em>
         <em>
          pertussis
         </em>
         (every 10 years, according to the standard adult vaccination schedule)  (
         <a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">
          figure 1
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         COVID-19 (coronavirus disease 2019), according to the age-based schedule  (
         <a class="graphic graphic_table graphicRef130711" href="/z/d/graphic/130711.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Respiratory syncytial virus, for those age ≥60 years [
         <a href="#rid32">
          32
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There have been several reports of AE-IPF following COVID-19 mRNA vaccine administration [
         <a href="#rid33">
          33-36
         </a>
         ]. However, both case reports [
         <a href="#rid37">
          37-39
         </a>
         ] and clinical experience inform us that infection with COVID-19 poses a larger risk for respiratory failure than vaccination in patients with IPF. Until further data are available on the relative risks of acute exacerbations with different vaccine formulations, we continue to recommend vaccination with any approved vaccine against COVID-19. (See
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">
          "Pneumococcal vaccination in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early outpatient treatment of respiratory infection
         </strong>
         – Treatment includes antibiotics for possible or verified bacterial pneumonia and
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         in the setting of influenza A infection. Patients with IPF are designated by the CDC as persons at risk for severe COVID-19  (
         <a class="graphic graphic_table graphicRef127477" href="/z/d/graphic/127477.html" rel="external">
          table 2
         </a>
         ) and therefore qualify for prioritized access to antiviral therapies, including nirmatrelvir/
         <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">
          ritonavir
         </a>
         and
         <a class="drug drug_general" data-topicid="127259" href="/z/d/drug information/127259.html" rel="external">
          remdesivir
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">
          "Seasonal influenza in nonpregnant adults: Treatment", section on 'Patients at risk for complications or severe illness'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">
          "COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Treatment with COVID-19-specific therapies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and treatment of recurrent aspiration
         </strong>
         – Patients with IPF should be screened clinically for oropharyngeal dysphagia with a low threshold for formal evaluation [
         <a href="#rid40">
          40
         </a>
         ]. Speech therapy to improve swallow function and appropriate dietary interventions should be strongly encouraged. Pharmacologic treatment of reflux disease is reasonable in patients with symptomatic gastroesophageal reflux, with consideration of surgical options in patients with severe disease. Empiric treatment of reflux in asymptomatic patients is not recommended. (See
         <a class="local">
          'Empiric treatment for asymptomatic gastroesophageal reflux'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoidance of mechanical ventilation
         </strong>
         – Elective procedures should be performed under local and regional anesthesia with spontaneous ventilation rather than with mechanical ventilation, when possible. Use of noninvasive ventilation via face mask, nasal device, or laryngeal mask airway is
         <strong>
          not
         </strong>
         protective against lung injury and may worsen aspiration risk.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoidance of harmful therapies
         </strong>
         – Several pharmacologic interventions have been found to be harmful to patients with IPF in large clinical trials. These include the combination of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , and N-acetyl cysteine [
         <a href="#rid41">
          41
         </a>
         ],
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         in patients without an additional indication for anticoagulation [
         <a href="#rid42">
          42
         </a>
         ], and
         <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">
          ambrisentan
         </a>
         [
         <a href="#rid43">
          43
         </a>
         ]. In general, we avoid broadly immunosuppressive therapies unless the patient has a strong alternative indication. (See
         <a class="local">
          'Therapies without clear benefit'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1243838735">
         <span class="h2">
          Palliative care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Palliative care aims to relieve suffering at all stages of disease and is not limited to end-of-life care [
         <a href="#rid44">
          44-46
         </a>
         ]. Palliative measures (eg, facial cooling with a fan, opioids, anxiolytics) may be helpful for patients with refractory dyspnea or cough. Patients with advanced IPF may benefit from hospice care  (
         <a class="graphic graphic_table graphicRef87287" href="/z/d/graphic/87287.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef61282" href="/z/d/graphic/61282.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/14238.html" rel="external">
          "Assessment and management of dyspnea in palliative care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83242.html" rel="external">
          "Palliative care: Overview of cough, stridor, and hemoptysis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86307.html" rel="external">
          "Palliative care for adults with nonmalignant chronic lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13191574">
         <span class="h1">
          MEDICAL THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         No medication has been found to cure IPF, but two antifibrotic medications,
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         and
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         , appear to slow disease progression and reduce the frequency of acute exacerbations [
         <a href="#rid2">
          2,4,47,48
         </a>
         ]. In addition, these agents appear to have a mortality benefit [
         <a href="#rid48">
          48,49
         </a>
         ]. A meta-analysis of trials and cohorts that included 12,956 patients with IPF showed that antifibrotic treatment (nintedanib or pirfenidone) was associated with a decreased risk of all-cause mortality (pooled risk ratio [RR] 0.55, 95% CI 0.45-0.66) and a decreased risk of acute exacerbations (RR 0.63, 95% CI 0.53-0.76) [
         <a href="#rid48">
          48
         </a>
         ]. A large cohort analysis of nearly 50,000 patients with IPF in the United States (24 percent had received antifibrotic treatment) found a significantly improved estimated all-cause mortality (HR 0.69, 95% CI 0.66-0.72) after adjustment for covariates [
         <a href="#rid50">
          50
         </a>
         ]. In the United States, racial disparities in antifibrotic treatments may adversely impact Black patients [
         <a href="#rid51">
          51
         </a>
         ]; we strongly urge physicians to closely examine their prescribing patterns to ensure equitable care for all racial and ethnic groups.
        </p>
        <p class="headingAnchor" id="H471583217">
         <span class="h2">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with mild or moderate IPF based on pulmonary function tests who do not have underlying liver disease, we recommend initiating therapy with either
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         or
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         [
         <a href="#rid4">
          4
         </a>
         ]. Current data are insufficient to direct a firm choice between pirfenidone and nintedanib, and the choice sometimes must be made based on availability. When there is a choice of agent, patient preference and tolerances should be considered, particularly regarding potential adverse effects, such as diarrhea with nintedanib versus nausea and rash with pirfenidone. (See
         <a class="local">
          'Nintedanib'
         </a>
         below and
         <a class="local">
          'Pirfenidone'
         </a>
         below.)
        </p>
        <p>
         In addition, for patients with more advanced IPF (forced vital capacity [FVC] &lt;50 percent predicted and/or diffusing capacity [DLCO] &lt;35 percent predicted), we suggest using one of these two agents. The decision is less clear, as these patients were excluded from the major clinical trials. Observational studies suggest that both agents slow disease progression in patients with more advanced disease to a similar extent as that seen in treated patients with less advanced disease [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
         Studies examining the combination of
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         and
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         are discussed below. As none of these agents are curative, we also provide patients with information about clinical trials. (See
         <a class="local">
          'Combination nintedanib plus pirfenidone'
         </a>
         below and
         <a class="local">
          'Clinical trials'
         </a>
         below.)
        </p>
        <p>
         Patients with severe pulmonary hypertension (eg, echocardiographic estimated systolic pulmonary artery pressure ≥60 mmHg) due to advanced IPF should be referred to a specialized pulmonary hypertension center for management. Use of inhaled
         <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">
          treprostinil
         </a>
         may be beneficial in this population. Other advanced therapies for pulmonary arterial hypertension (eg, systemic prostanoids,
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         ) may be helpful in select patients with IPF, although trials of oral pulmonary vasodilators have not demonstrated benefit in clinical trials. The use of systemic pulmonary vasodilators risks worsening ventilation-perfusion matching and increasing hypoxemia and should be performed with caution in advanced centers. (See
         <a class="local">
          'Therapies without clear benefit'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/8258.html" rel="external">
          "Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H204497416">
         <span class="h2">
          Nintedanib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          Nintedanib
         </a>
         , a receptor blocker for multiple tyrosine kinases that mediate elaboration of fibrogenic growth factors (eg, platelet-derived growth factor, vascular endothelial growth factor (VEGF), fibroblast growth factor), slows the rate of disease progression in IPF [
         <a href="#rid54">
          54,55
         </a>
         ]. Nintedanib has been approved by the US Food and Drug Administration, the European Medicines Agency, and a number of other countries [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3031551">
         <span class="h3">
          Dose and administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The standard dose of
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         is 150 mg twice daily, approximately 12 hours apart. Liver function tests (LFTs; alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin) should be assessed prior to initiation of nintedanib; patients with moderate or severe hepatic impairment (Child Pugh B or C) should not take nintedanib [
         <a href="#rid57">
          57
         </a>
         ]. After initiation, LFTs should be repeated monthly for three months, every three months thereafter, and as clinically indicated. Dose modification or interruption may be necessary for liver enzyme elevations. A pregnancy test should be performed prior to initiation of therapy in women of child-bearing age, and conception avoided until at least three months after the last dose [
         <a href="#rid57">
          57
         </a>
         ]. Nintedanib has not been studied in patients with creatinine clearance &lt;30 mL/min. It should be used with caution in patients with kidney impairment given reports of proteinuria and other kidney toxicity with use of nintedanib and other VEGF inhibitors [
         <a href="#rid58">
          58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Class side effects of VEGF inhibitors'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          Nintedanib
         </a>
         interacts with P-glycoprotein and CYP3A4 inhibitors and inducers and may also increase the risk of bleeding among patients on full anticoagulation.
        </p>
        <p>
         The most frequent adverse effects associated with
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         are diarrhea (62 percent), nausea (24 percent), vomiting (12 percent), and elevation in LFTs (14 percent), which were greater than five times normal in 6 percent [
         <a href="#rid55">
          55,57
         </a>
         ]. In clinical trials, diarrhea was treated with hydration, antidiarrheal medication (eg,
         <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">
          loperamide
         </a>
         ), and sometimes reduction in the dose to 100 mg twice daily. If the lower dose was not tolerated, treatment was interrupted. Diarrhea led to permanent dose reduction in 11 percent of patients and to discontinuation in 5 percent. Observational studies in real-world settings suggest higher rates of dose reduction (20 to 30 percent) and variable rates of drug discontinuation (5 percent to 25 percent) due to gastrointestinal side effects [
         <a href="#rid59">
          59-62
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3134190527">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In clinical trials, the main benefits of
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         are a reduction in the rate of decline in lung function and a longer time to first exacerbation [
         <a href="#rid52">
          52,55,63-66
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          Nintedanib
         </a>
         (BIBF 1120) showed promising results in a phase 2 trial (To Improve Pulmonary Fibrosis with BIBF 1120, TOMORROW) [
         <a href="#rid63">
          63
         </a>
         ]. A total of 432 patients were randomly assigned to one of four oral doses of BIBF 1120 or placebo. The group taking the highest dose of BIBF 1120, 150 mg twice daily, showed a trend toward a slower decline in lung function and fewer exacerbations compared with placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a two-year extension of the TOMORROW trial, FVC decline was significantly less in patients taking
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         150 mg twice a day compared with placebo or a lower dose of nintedanib (125.4 mL/year versus 189.7 mL/year) [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In two subsequent trials (INPULSIS-1 and INPULSIS-2), a total of 1066 patients with IPF were randomly assigned to
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         150 mg or placebo twice daily for 52 weeks [
         <a href="#rid55">
          55
         </a>
         ]. In INPULSIS-1, the annual rate of decline in FVC was lower in the nintedanib group than the placebo group with a difference of 125.3 mL/year (95% CI 77.7-172.8). The results were similar in INPULSIS-2 where the difference in FVC decline was 93.7 mL/year (95% CI 44.8-142.7). In INPULSIS-1, no difference between nintedanib and placebo was noted in the time to first exacerbation, but in INPULSIS-2, an increase in the time to first exacerbation was noted (hazard ratio [HR] 0.38, 95% CI 0.19-0.77).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional subgroup analysis of data from this trial showed that the treatment effects appeared more pronounced in subjects with baseline FVC ≤70 percent predicted [
         <a href="#rid64">
          64
         </a>
         ]. A separate post-hoc analysis (1061 participants) examined the annual rate of decline in FVC over the 52 weeks of INPULSIS; among patients taking
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         , 25 percent had improvement or lack of decline in FVC, compared with 9 percent of those taking placebo [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a combined analysis of data from the TOMORROW trial and the two INPULSIS trials [
         <a href="#rid55">
          55,63
         </a>
         ],
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         significantly reduced the risk of acute exacerbation (HR 0.53, 95% CI 0.34-0.83) [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The tyrosine kinase inhibitor,
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , inhibits a narrower spectrum of growth factors than
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         and had no effect on survival or lung function in IPF when compared with placebo [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3958970711">
         <span class="h3">
          Role in more advanced disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on observational data,
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         appears to have a similar effect in slowing decline in pulmonary function tests among patients with more advanced disease, compared with patients with less advanced disease [
         <a href="#rid53">
          53,69,70
         </a>
         ]. However, studies have not demonstrated a benefit in activities of daily living or survival, and adverse effects are frequent, leading to high treatment discontinuation.
        </p>
        <p>
         In a prospective study,
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         was administered to 108 patients with IPF, of whom 51 (47 percent) had advanced disease (FVC &lt;50 percent predicted or DLCO &lt;30 percent predicted) [
         <a href="#rid70">
          70
         </a>
         ]. The rate of disease progression (≥10 percent absolute decline in FVC over 12 months) in the advanced disease group decreased in the 12 months after treatment initiation, compared with the 12 months before (9 versus 79 percent, p&lt;0.001). Declines in FVC and DLCO in the advanced group paralleled those in the nonadvanced disease group. Adverse events were common, including diarrhea (50 percent) and anorexia (45 percent). While similar in occurrence between the two groups, they are more likely to lead to treatment discontinuation in the advanced group.
        </p>
        <p>
         A separate observational study of 41 patients with advanced IPF (FVC ≤50 percent of predicted and/or DLCO ≤35 percent predicted) compared lung function decline during
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         treatment with the six months prior to initiation [
         <a href="#rid53">
          53
         </a>
         ]. The decline in DLCO (both absolute and percent predicted) was lower during nintedanib treatment than in the pretreatment period, but no difference was noted in FVC decline.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Pirfenidone
         </span>
         <span class="headingEndMark">
          —
         </span>
         The predominant pathological findings in IPF are fibroblast foci, collagen deposition, and minimal inflammatory cell infiltration, raising the possibility that antifibrotic agents might slow the rate of disease progression [
         <a href="#rid71">
          71,72
         </a>
         ].
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          Pirfenidone
         </a>
         is an antifibrotic agent that inhibits transforming growth factor beta (TGF-b)-stimulated collagen synthesis, decreases the extracellular matrix, and blocks fibroblast proliferation in vitro. (See
         <a class="medical medical_review" href="/z/d/html/4300.html" rel="external">
          "Pathogenesis of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          Pirfenidone
         </a>
         is approved for marketing in a number of countries, including (among others) Germany, France, the United Kingdom, Canada, Japan, and the United States.
        </p>
        <p class="headingAnchor" id="H175732739">
         <span class="h3">
          Dose and administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dose of
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         ranges up to 40 mg/kg per day (to maximum of 2403 mg per day) in three divided doses. Pirfenidone is initiated at a dose of 267 mg (1 capsule) three times a day. After one week, the dose is increased to 534 mg (two capsules) three times a day, and after the second week to the full dose of 801 mg (three capsules) three times a day. Pirfenidone should always be taken with food.
        </p>
        <p>
         The most common side effects include rash (30 percent), photosensitivity (9 percent), nausea (36 percent), diarrhea (26 percent), abdominal discomfort (24 percent), dyspepsia (19 percent), anorexia (13 percent), and fatigue (26 percent) [
         <a href="#rid73">
          73
         </a>
         ]. Other potential side effects include diarrhea, constipation, itching, dry skin, hyperpigmentation, headache, and weakness. Although most rashes are minor, severe cutaneous adverse reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. Confirmation of any of these reactions precludes further treatment with
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         .
        </p>
        <p>
         In the CAPACITY trials (described further below), dose reduction or interruption for gastrointestinal events was required in 18 percent of patients in the 2403 mg/day group, and 2 percent discontinued study medication. In a separate study, pirfenidone-associated gastrointestinal side effects occurred less frequently in those eating a diet high in mono-unsaturated fatty acids compared with those with diets high in saturated fatty acids (27 versus 65 percent) [
         <a href="#rid74">
          74
         </a>
         ]. Taking the medication after meals may improve the gastrointestinal side effects [
         <a href="#rid75">
          75
         </a>
         ]. Diet adjustments have not been well studied, but a trial of a Mediterranean-style diet may also be reasonable based on these data.
        </p>
        <p>
         Drug-induced liver disease can occur and ranges from mild elevations in LFTs to serious or fatal liver injury [
         <a href="#rid76">
          76
         </a>
         ]. Elevations in LFTs three times the upper limit of normal or higher occurred in 4 percent of patients in phase 3 trials [
         <a href="#rid73">
          73
         </a>
         ]. All LFT elevations resolved with dose modification or treatment discontinuation. LFTs (eg, ALT, AST, bilirubin) should be obtained prior to initiation of therapy and at regular intervals during therapy (eg, approximately monthly for the first six months and at three month intervals thereafter and as clinically indicated) [
         <a href="#rid73">
          73
         </a>
         ]. Elevations in the ALT and/or AST may require a reduction or interruption in dose.
        </p>
        <p>
         In kidney impairment, there is an accumulation of potentially active metabolites [
         <a href="#rid77">
          77
         </a>
         ]. Based on this data, European regulators do not recommend use of
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         in patients with CrCl &lt;30 mL/min; United States prescribing information suggests close monitoring and possible need for dose adjustment. In small open-label trials including patients with eGFR 15 to 30 mL/min/1.73m
         <sup>
          2
         </sup>
         , side effect profiles were similar to those of patients without impaired kidney function, but drop-out rates were high (35 to 45 percent), even after dose reduction [
         <a href="#rid78">
          78,79
         </a>
         ]. A slower titration (dose increases every two to three weeks) is indicated in the setting of CrCl &lt;30 mL/min and pirfenidone should not be given to patients with CrCl &lt;15 mL/min
         <sup>
         </sup>
         or patients on dialysis.
        </p>
        <p>
         The dose of
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         should be reduced in the presence of strong or moderate CYP1A2 inhibitors (eg,
         <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">
          fluvoxamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ) [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1538156993">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with mild-to-moderate disease based on pulmonary function tests who are not interested in participating in a clinical trial and live in an area where
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         is available, we recommend initiation of pirfenidone [
         <a href="#rid4">
          4
         </a>
         ]. This recommendation is based upon data from randomized trials and case series that have shown a beneficial effect of pirfenidone in slowing the progression of IPF when administered to patients with mild-to-moderate disease and a possible mortality benefit in a pooled analysis [
         <a href="#rid80">
          80-87
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the ASsessment of
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         to Confirm Efficacy aND safety in idiopathic pulmonary fibrosis (ASCEND) trial, 555 patients with IPF were randomly assigned to receive oral pirfenidone (2403 mg per day) or placebo for 52 weeks [
         <a href="#rid88">
          88
         </a>
         ]. Pirfenidone resulted in a significant reduction in the one-year rate of decline in FVC; the proportion of patients in the pirfenidone group who had a decline of 10 percentage points or more in the percent of predicted FVC or died was reduced by 48 percent compared with the placebo group (46 patients [16.5 percent] versus 88 patients [31.8 percent]), respectively. Nearly 23 percent of the pirfenidone group had no decline in percent of predicted FVC at week 52, compared with 10 percent of the placebo group, representing a more than 133 percent increase in the proportion of patients with no evidence of FVC decline. As secondary end-points, pirfenidone reduced the rate of decline in the six-minute walk difference and improved progression-free survival compared with placebo but did not reduce dyspnea. In a prespecified analysis that pooled results of the ASCEND trial with two prior trials (CAPACITY 004 and 006; 1247 total patients) [
         <a href="#rid83">
          83
         </a>
         ], pirfenidone decreased death from any cause relative to placebo (22 [3.5 percent] in the pirfenidone group as compared with 42 [6.7 percent] in the placebo group; HR 0.52, 95% CI 0.31-0.87). As the ASCEND trial was 52 weeks in duration, the pooled survival analysis only considered data from the first 52 weeks of the CAPACITY trials (which were 72 weeks in duration). A separate pooled analysis considering all available data on all-cause mortality showed a trend favoring pirfenidone but was not statistically significant (Kaplan-Meier estimate 0.75, 95% CI 0.51-1.11).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two concurrent, multicenter trials (Clinical studies Assessing
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          Pirfenidone
         </a>
         in idiopathic pulmonary fibrosis, CAPACITY 004 and 006) assessed the change in percentage FVC at week 72 [
         <a href="#rid83">
          83
         </a>
         ]. Patients with mild-to-moderate IPF (ie, FVC ≥50 percent predicted and DLCO ≥35 percent predicted) were randomly assigned to oral pirfenidone 2403 mg/day, 1197 mg/day, or placebo in the 004 trial and oral pirfenidone 2403 mg/day or placebo in the 006 trial. The higher dose of pirfenidone significantly decreased the percent fall in FVC in the 004 trial (difference between groups 4.4 percent, p = 0.001) but not the 006 trial (difference between groups 0.6 percent, p = 0.51). The higher dose of pirfenidone significantly reduced the decline in the six-minute walk test, a secondary endpoint, in the 006 (absolute difference 32 meters, p = 0.0009), but not the 004 trial.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial of
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         (1800 mg/day) versus placebo was carried out in 107 patients with IPF [
         <a href="#rid81">
          81
         </a>
         ]. The change in the lowest oxygen saturation by pulse oximetry (SpO
         <sub>
          2
         </sub>
         ) during a six-minute exercise test, the primary endpoint, was not significantly different between the two groups from baseline to six months (+0.6 versus -0.5 percent) and nine months (+0.5 versus -0.9 percent). In a prespecified subset of patients who maintained the SpO
         <sub>
          2
         </sub>
         &gt;80 percent during a six-minute exercise test at baseline, a significant improvement was noted in the pirfenidone group in the lowest SpO
         <sub>
          2
         </sub>
         that occurred during a six-minute exercise test at six months (+0.5 versus -1.9 percent) and nine months (+0.5 versus -1.6 percent), suggesting there may be greater benefit in patients whose disease is less severe.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the same trial, a positive treatment effect was demonstrated in secondary endpoints including an increase in vital capacity (VC) measurements at nine months (-0.03 versus -0.13 liters) and fewer episodes of acute exacerbation of IPF (14 percent versus none). The trial was aborted in favor of
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         treatment due to the decreased number of acute exacerbations in the pirfenidone group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a separate multicenter trial, 275 patients were randomly assigned to one of three groups:
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         1800 mg per day, 1200 mg per day, or placebo [
         <a href="#rid82">
          82
         </a>
         ]. The primary endpoint, change in VC, was assessed at 52 weeks; the secondary endpoint was progression-free survival. The decline in VC was only slightly less in the high-dose pirfenidone group compared with placebo, but the difference was statistically significant. The progression-free survival time was slightly longer in the high-dose pirfenidone group compared with placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pooled analysis of ASCEND and CAPACITY 004 and 006 study data demonstrated that patients treated with
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         for one year were &gt;40 percent less likely to reach the threshold of a 10 percent fall in FVC or death and 38 percent less likely to progress at all, compared with those on placebo [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a follow-up to the original ASCEND and CAPACITY trials, 34 subjects on
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         and 68 subjects on placebo who experienced a ≥10 percent decline in FVC in the first three or six months were assessed again six months later [
         <a href="#rid89">
          89
         </a>
         ]. Fewer subjects in the pirfenidone group experienced a further ≥10 percent decline in FVC or death in the following six months compared with the placebo group (2 of 34 versus 19 of 68, respectively, p&lt;0.009). While the numbers are small, this study suggests that continued pirfenidone treatment may be of benefit in patients despite initial evidence of disease progression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pooled analysis of the combined patient populations of the three global randomized phase 3 trials of
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         versus placebo (CAPACITY 004 and 006 and ASCEND) and a meta-analyses of two Japanese trials showed a reduction in treatment-emergent all-cause mortality, idiopathic-pulmonary-fibrosis-related mortality, and treatment-emergent idiopathic-pulmonary-fibrosis-related mortality for pirfenidone therapy compared with placebo [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          Pirfenidone
         </a>
         appears to slow the progression of lung impairment in patients with pulmonary fibrosis due to Hermansky-Pudlak syndrome [
         <a href="#rid91">
          91
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/115158.html" rel="external">
          "Hermansky-Pudlak syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H803740102">
         <span class="h3">
          Role in more advanced disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies of
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         in patients with more advanced disease are limited, as these patients were excluded in the pivotal trials described above (see
         <a class="local">
          'Efficacy'
         </a>
         above). However, subsequent data suggest that the efficacy of pirfenidone in slowing decline in FVC is similar across the range of disease severity [
         <a href="#rid92">
          92-95
         </a>
         ]. Further study is needed to determine whether pirfenidone has a benefit in terms of quality of life and/or survival.
        </p>
        <p>
         A post-hoc analysis of the open-label extension study RECAP included 187 patients with more advanced IPF (FVC &lt;50 percent predicted and/or DLCO &lt;35 percent predicted), while 409 patients had less advanced disease (FVC ≥50 percent predicted and/or DLCO ≥35 percent predicted) [
         <a href="#rid93">
          93
         </a>
         ]. Of the patients with more advanced disease, 100 had received
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         during the CAPACITY trial and 87 received placebo; all of the patients transitioned to pirfenidone at the start of RECAP. During the 180 weeks of RECAP, the decline in mean percent-predicted FVC in the group with more advanced disease paralleled that of the group with less advanced disease. Adverse events related to IPF progression (eg, dyspnea, worsening of IPF) were more common among those with more advanced than less advanced disease, as was discontinuation of study drug (72 versus 43 percent).
        </p>
        <p class="headingAnchor" id="H2933232007">
         <span class="h2">
          Clinical trials
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best hope for patients with IPF is that carefully performed clinical trials will confirm the efficacy and safety of agents that are identified based on animal models of IPF. We encourage appropriate patients to participate in clinical trials of emerging therapies for IPF. Specific trials and registries are available for patients with a familial history of IPF. Inclusion and exclusion criteria for clinical trials vary, so we provide all patients with information regarding participation in randomized clinical trials whenever appropriate trials are available. Patients with mild-to-moderate disease are frequently ideal candidates for clinical trials as many trials limit participation to patients with early disease.
        </p>
        <p>
         Clinical trial information is available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=4328" target="_blank">
          ClinicalTrials.gov
         </a>
         . Information about research into the genetic factors that may contribute to the development of familial IPF is available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT01088217&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzAkSY5n%2FX2L3JQIvZm2ojs0%2BHQkBFZZ84AsHpS5zY1XA%3D%3D&amp;TOPIC_ID=4328" target="_blank">
          ClinicalTrials.gov: Genetics of IPF
         </a>
         .
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h1">
          LUNG TRANSPLANTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         IPF is the most common interstitial lung disease among referrals for lung transplantation and the second most frequent disease for which lung transplantation is performed [
         <a href="#rid96">
          96
         </a>
         ]. The median survival following lung transplantation for IPF is estimated to be 5.2 years  (
         <a class="graphic graphic_figure graphicRef57297" href="/z/d/graphic/57297.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h2">
          Indications and choice of procedure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with IPF have the highest death rate among the diagnostic groups on the transplant waiting list [
         <a href="#rid97">
          97
         </a>
         ]. For this reason, early referral for transplant evaluation should be considered, even before the response to initial medical therapy has been determined [
         <a href="#rid98">
          98-100
         </a>
         ]. Under the current United Network for Organ Sharing (UNOS) system, priority for transplantation is determined by medical urgency and expected outcome using a lung composite allocation score (CAS)  (
         <a class="graphic graphic_table graphicRef59818" href="/z/d/graphic/59818.html" rel="external">
          table 5
         </a>
         ). Scores are normalized to a continuous scale from 0 to 100, with higher scores representing higher priority, in part based on higher expected waiting list mortality and greater potential transplant benefit. (See
         <a class="medical medical_review" href="/z/d/html/4659.html" rel="external">
          "Lung transplantation: An overview", section on 'Lung allocation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4660.html" rel="external">
          "Lung transplantation: Disease-based choice of procedure"
         </a>
         .)
        </p>
        <p>
         General guidelines for timing of referral for transplantation include histologic or radiographic evidence of usual interstitial pneumonia (UIP) and the following [
         <a href="#rid101">
          101
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A diffusing capacity (DLCO) &lt;40 percent of predicted
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A forced vital capacity (FVC) &lt;80 percent of predicted
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any dyspnea or functional limitation attributable to lung disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A decrease in pulse oximetry below 89 percent saturation, even if only during exertion
        </p>
        <p>
        </p>
        <p>
         Criteria for placing on transplant list include the following [
         <a href="#rid101">
          101
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decline in FVC ≥10 percent during six months of follow-up (a decline ≥5 percent may also warrant listing)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decline in DLCO ≥15 percent during six months of follow-up
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         On six-minute walk test: oxygen desaturation to &lt;88 percent or distance walked &lt;250 meters or &gt;50 meter decline in distance walked over six months
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary hypertension on right heart catheterization or transthoracic echocardiogram
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hospitalization because of respiratory decline, pneumothorax, or acute exacerbation
        </p>
        <p>
        </p>
        <p>
         Although single lung transplantation (SLT) has been the standard procedure for IPF, bilateral lung transplant (BLT) may prove to have better long-term survival [
         <a href="#rid96">
          96,102-105
         </a>
         ]. Mild-to-moderate secondary pulmonary hypertension preoperatively increased the risk of reperfusion injury in one study but did not appear to affect survival in two retrospective studies [
         <a href="#rid106">
          106,107
         </a>
         ].
        </p>
        <p>
         Following SLT, the low lung compliance and high vascular resistance of the remaining native lung preferentially direct both ventilation and perfusion to the transplanted lung. Cysts, bullae, and bronchiectasis that occasionally develop in the later stages of IPF can act as a nidus for infectious complications after SLT; when these are identified, BLT may be preferred.
        </p>
        <p>
         Early experience suggests that living donor lobar lung transplantation (LDLLT) may be an option for patients with IPF who are likely to die while waiting for SLT. In a report of nine such patients, eight of whom were dependent on systemic glucocorticoids (up to 50 mg/day), only one early death occurred after transplant of two lower lobes donated by two healthy relatives [
         <a href="#rid108">
          108
         </a>
         ]. Eight patients were still alive after 10 to 48 months of follow-up.
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h2">
          Physiologic changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         After SLT or BLT, spirometric parameters, lung volumes, diffusing capacity, and oxygenation improve significantly and these improvements have been sustained in long-term follow-up of recipients without complications [
         <a href="#rid109">
          109-112
         </a>
         ]. In a series that compared SLT and BLT recipients with IPF, the mean forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) was higher in BLT recipients than SLT recipients one year after transplantation (2.25 versus 2.00 liters) [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
         After SLT, most lung function is contributed by the allograft. As a result, the vital capacity (VC) of the recipient correlates closely with the predicted VC of the donor organ [
         <a href="#rid113">
          113
         </a>
         ]. Improvements in cardiopulmonary function continue for up to one year following transplantation. As an example, in one study of SLT recipients, the mean VC increased from 43 percent of the predicted normal value preoperatively to 65 percent three months and 69 percent one year after transplantation. None of the eight recipients tested one year after transplantation required supplemental oxygen at rest or during exercise, and their treadmill exercise tolerance was much improved [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h2">
          Factors that may increase the risk of transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations in the genes that contribute to maintenance of telomere length and pretransplant systemic glucocorticoid use may increase the risk of adverse outcomes following lung transplantation.
        </p>
        <p class="headingAnchor" id="H3904227566">
         <span class="h3">
          Telomerase complex mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations in the telomerase complex (eg, TERT and TR) are associated with IPF and also with hematologic manifestations such as myelodysplasia, which may place patients undergoing lung transplantation at risk for adverse hematologic outcomes [
         <a href="#rid114">
          114-118
         </a>
         ]. Among nine patients with TERT or TR mutations who underwent lung transplantation for IPF, six developed bone marrow failure and/or myelodysplasia, which contributed to death in four patients [
         <a href="#rid114">
          114
         </a>
         ]. Thrombocytopenia was present in seven patients prior to surgery. Postoperatively, anemia developed in all of the patients, and neutropenia developed in three. In a separate series, eight patients with telomerase mutations received lung allografts and were noted to have a greater need for platelet transfusion and adjustment of the immunosuppressive regimen compared with historic controls. However, seven patients were alive after a median follow-up of 1.9 years (range six months to nine years) [
         <a href="#rid115">
          115
         </a>
         ]. While long-term survival following lung transplant appears feasible, careful assessment of hematologic status is appropriate prior to lung transplantation [
         <a href="#rid116">
          116,118
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/100663.html" rel="external">
          "Dyskeratosis congenita and other telomere biology disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1804266414">
         <span class="h3">
          Glucocorticoid therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The effect of prior glucocorticoid therapy on the outcome of lung transplantation is uncertain. Most studies suggest that low-dose glucocorticoid therapy has no adverse effect on outcome [
         <a href="#rid119">
          119-121
         </a>
         ]. However, high-dose glucocorticoid therapy may be associated with decreased survival after lung transplantation [
         <a href="#rid121">
          121
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">
          "Lung transplantation: General guidelines for recipient selection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H39">
         <span class="h1">
          THERAPIES WITHOUT CLEAR BENEFIT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several agents have been evaluated for use in IPF but are not currently used for this indication. The following agents are mentioned here to provide clinicians with an overview of the evidence for and against their use.
        </p>
        <p class="headingAnchor" id="H2374645021">
         <span class="h2">
          Empiric treatment for asymptomatic gastroesophageal reflux
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although observational and genetic data indicate a possible role for gastroesophageal reflux (GER) in IPF pathogenesis and progression [
         <a href="#rid122">
          122-129
         </a>
         ], we suggest not treating patients who have IPF with empiric pharmacologic or surgical treatment of GER. However, use of these therapies for symptomatic relief or esophageal disease in patients with confirmed GER may be appropriate. Our approach is consistent with guidelines from major expert panels [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p>
         GER is common among patients with IPF [
         <a href="#rid131">
          131-133
         </a>
         ]. In a systematic review, it was noted that 67 to 76 percent of patients with IPF assessed with ambulatory pH probe monitoring had abnormal distal esophageal acid exposure [
         <a href="#rid134">
          134
         </a>
         ].
        </p>
        <p>
         However, a pooled analysis of post-hoc data from randomized trials found that antacid medications led to a small and statistically insignificant benefit on disease progression, as defined by 10 percent decline in forced vital capacity (FVC), 50 m decline in six-minute walk test, or death (risk ratio [RR] 0.88, 95% CI 0.76-1.03) [
         <a href="#rid135">
          135
         </a>
         ]. Additional observational data pointed to a lack of effect on mortality, hospitalization, or lung function outcomes.
        </p>
        <p>
         One small unblinded trial of 58 patients compared antireflux surgery to no intervention [
         <a href="#rid136">
          136
         </a>
         ]. There was a trend toward reduced overall mortality at 48 weeks in those receiving antireflux surgery (3 versus 14 percent, RR 0.25, 95% CI 0.03-2.10). Similar findings were seen for adjudicated exacerbation rates. A separate observational study reported a smaller trend toward improved mortality at 48 weeks (hazard ratio [HR] 0.74, 95% CI 0.21-2.59) [
         <a href="#rid137">
          137
         </a>
         ]. No differences were seen in hospitalizations or lung function parameters in either of these studies. Severe surgical complications are common (9 percent in one systematic review) [
         <a href="#rid135">
          135
         </a>
         ]. These complications included gastric perforation, severe intraoperative bleeding, rehospitalization for nausea or dysphagia, or need for esophageal dilation.
        </p>
        <p class="headingAnchor" id="H86165214">
         <span class="h2">
          Anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapeutic anticoagulation of patients with IPF using
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         was investigated due to observational evidence of a possible IPF-mediated prothrombotic state [
         <a href="#rid138">
          138,139
         </a>
         ], but this strategy is not recommended due to evidence of increased mortality.
        </p>
        <p>
         After a small unblinded trial showed possible benefit from
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         anticoagulation [
         <a href="#rid140">
          140
         </a>
         ], the Anticoagulant Effectiveness in Idiopathic Pulmonary Fibrosis trial (ACE-IPF) was performed [
         <a href="#rid42">
          42,141,142
         </a>
         ]. In ACE-IPF, 145 patients with IPF but without other indications for anticoagulation were randomly assigned to therapeutic warfarin or placebo [
         <a href="#rid42">
          42
         </a>
         ]. The study was stopped at 28 weeks due to an increase in mortality in the patients assigned warfarin (14 versus 3 deaths). None of the deaths were attributed to bleeding complications.
        </p>
        <p>
         Anticoagulation may still be appropriate in patients with IPF if there are other indications (eg, pulmonary embolism).
        </p>
        <p class="headingAnchor" id="H1239057848">
         <span class="h2">
          Maintenance antibiotic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alteration of the lung microbiome occurs in patients with IPF [
         <a href="#rid143">
          143,144
         </a>
         ] and may influence disease progression and exacerbations [
         <a href="#rid145">
          145
         </a>
         ]. However, randomized trials of maintenance
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         or
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         failed to show an effect on time to nonelective hospitalization, mortality, or other secondary clinical outcomes compared with usual care [
         <a href="#rid146">
          146,147
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12224043">
         <span class="h2">
          Azathioprine, prednisone, and (N) acetylcysteine
         </span>
         <span class="headingEndMark">
          —
         </span>
         The historical strategy of treating patients with IPF using
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , and (N)
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          acetylcysteine
         </a>
         (NAC) is harmful and should
         <strong>
          not
         </strong>
         be used. The multicenter PANTHER trial (Prednisone, Azathioprine, and NAC: A Study That Evaluates Response in IPF) found that, compared with placebo, combination therapy (prednisone-azathioprine-NAC) was associated with greater mortality (8 versus 1 deaths), more hospitalizations (23 versus 7), and more serious adverse events (24 versus 8) [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H74873394">
         <span class="h2">
          (N) acetylcysteine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although lung injury from excess production of oxidants is thought to be a contributing factor in IPF [
         <a href="#rid148">
          148-154
         </a>
         ], the potent antioxidant NAC does not ameliorate the course of IPF [
         <a href="#rid150">
          150-153,155
         </a>
         ] and should not be used as monotherapy [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4300.html" rel="external">
          "Pathogenesis of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p>
         The PANTHER trial, also mentioned above, showed that NAC alone (1800 mg orally per day) did not slow the decline in FVC over 60 weeks compared with placebo [
         <a href="#rid41">
          41,156
         </a>
         ]. (See
         <a class="local">
          'Azathioprine, prednisone, and (N) acetylcysteine'
         </a>
         above.)
        </p>
        <p>
         Furthermore, NAC did not reduce deaths or acute exacerbations but appeared to increase the rate of serious adverse cardiac events (6.8 versus 1.5 percent).
        </p>
        <p class="headingAnchor" id="H1198351260">
         <span class="h2">
          Other immunosuppressants
         </span>
         <span class="headingEndMark">
          —
         </span>
         After the results of the PANTHER trial, which demonstrated harm from prednisone-azathioprine-NAC, we do not believe there is a role for broadly targeted immunosuppressants in the treatment of IPF. (See
         <a class="local">
          'Azathioprine, prednisone, and (N) acetylcysteine'
         </a>
         above and
         <a class="local">
          '(N) acetylcysteine'
         </a>
         above.)
        </p>
        <p>
         Based in part on the harms seen in PANTHER, we no longer use systemic glucocorticoid monotherapy in IPF treatment. Multiple studies have found lack of benefit for
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         in IPF [
         <a href="#rid157">
          157,158
         </a>
         ], and there have been no data to suggest a benefit of other broadly immunosuppressive agents such as
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         .
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          Colchicine
         </a>
         and interferon gamma-1b were similarly without benefit in clinical trials [
         <a href="#rid159">
          159-163
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2359946">
         <span class="h2">
          Endothelin receptor antagonists
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several trials examining the efficacy of endothelin receptor antagonists in IPF found that these agents were not beneficial and possibly harmful [
         <a href="#rid43">
          43,164-167
         </a>
         ]. This class of drugs is not being used in IPF treatment [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1449354925">
         <span class="h2">
          Phosphodiesterase-5 inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         A substantial portion of advanced IPF patients develop pulmonary hypertension (PH). However, trials of
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         in patients with advanced IPF have failed to show significant benefit [
         <a href="#rid4">
          4,168-172
         </a>
         ]. Sildenafil is therefore not routinely used in this setting. The use of phosphodiesterase inhibitors in PH is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8258.html" rel="external">
          "Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H284157217">
         <span class="h2">
          Collagen-modifying agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the plausible mechanism of impairing collagen deposition, there was no benefit from
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          penicillamine
         </a>
         in multiple observational studies [
         <a href="#rid162">
          162,173,174
         </a>
         ]. An investigational molecule targeting the collagen cross-linking enzyme lysyl-oxidase 2 (simtuzumab) was also shown to be ineffective [
         <a href="#rid175">
          175
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13191796">
         <span class="h1">
          FUTURE DIRECTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         None of the agents currently available for the treatment of IPF are curative. Therapeutic response is obtained in only a subset of patients, and survival is poor even for those who respond. In addition, these agents all carry significant side effects and toxicity. For these reasons, there is much interest in developing more effective, less toxic pharmacologic therapy [
         <a href="#rid176">
          176,177
         </a>
         ]. Some examples of potential future strategies are described below.
        </p>
        <p class="headingAnchor" id="H651111731">
         <span class="h2">
          Combination nintedanib plus pirfenidone
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          Nintedanib
         </a>
         and
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         slow but do not halt IPF progression (see
         <a class="local">
          'Medical therapies'
         </a>
         above). The potential benefit of combined therapy with these two agents is unclear. The safety and tolerability of this combination therapy has been evaluated, and fewer than 25 percent of patients on this combination need to stop therapy due to adverse events [
         <a href="#rid178">
          178-181
         </a>
         ].
        </p>
        <p>
         As an example, an open-label, phase 4 study assessed the safety and tolerability of treatment with
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         (1602 to 2403 mg/day) plus
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         (200 to 300 mg/day) in patients with IPF [
         <a href="#rid180">
          180
         </a>
         ]. The primary endpoint was safety and tolerability of this regimen. Combined pirfenidone and nintedanib use for 24 weeks was tolerated by the majority (78 percent) of patients and associated with a similar pattern of treatment-emergent adverse events as expected for either treatment alone.
        </p>
        <p class="headingAnchor" id="H1294175878">
         <span class="h2">
          Phosphodiesterase 4B inhibitor (BI 1015550)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phosphodiesterase 4 (PDE4) blockade, which prevents the degradation of cyclic adenosine monophosphate, has antifibrotic and immunomodulatory effects [
         <a href="#rid182">
          182
         </a>
         ]. The selective inhibition of the 4B isoform is expected to improve tolerability by reducing off-target side effects, particularly nausea, emesis, and diarrhea.
        </p>
        <p>
         In a phase 2 trial, 97 patients with IPF were randomly assigned to receive 18 mg of the PDE4 inhibitor BI 1015550 or placebo twice daily for 12 weeks. The group receiving BI 1015550 was compared with patients receiving placebo in this trial and in previous trials. In patients not taking antifibrotics, forced vital capacity (FVC) increased at 12 weeks with BI 1015550 and decreased with placebo (+5.7 versus -81.7 mL) [
         <a href="#rid183">
          183
         </a>
         ]. In patients receiving background antifibrotics, the benefit was smaller but still significant (+2.7 versus -59.2 mL). Ten patients on background antifibrotics and three patients not on background therapy stopped the drug for adverse events.
        </p>
        <p class="headingAnchor" id="H1122895281">
         <span class="h2">
          Pentraxin 2
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pentraxin 2 (serum amyloid P) inhibits monocyte differentiation into profibrotic fibrocytes or proinflammatory macrophages, as well as reduces the production of transforming growth factor (TGF)-beta1, a potent regulator of connective tissue synthesis. Pentraxin 2 concentrations are lower in plasma from patients with IPF than in healthy individuals [
         <a href="#rid184">
          184
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4300.html" rel="external">
          "Pathogenesis of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p>
         In a phase 2 trial, 111 patients with IPF, most of whom were treated with an antifibrotic agent, received recombinant human pentraxin 2 (10 mg/kg) or placebo intravenously every four weeks for 24 weeks. Patients in the pentraxin 2 group experienced slower decline in FVC (-2.5 versus -4.8 percent) [
         <a href="#rid185">
          185
         </a>
         ]. The most common adverse events were cough and fatigue. In a 76-week open-label extension, the patients who crossed over from placebo to pentraxin 2 showed slowed deterioration of lung function and six-minute walk distance similar to that seen in the initial study [
         <a href="#rid186">
          186
         </a>
         ]. Findings were consistent at 128 weeks [
         <a href="#rid187">
          187
         </a>
         ]. Pentraxin 2 was generally well-tolerated.
        </p>
        <p>
         A phase 3 placebo-controlled trial (STARSCAPE) evaluating the efficacy and safety of recombinant human pentraxin-2 (rhptx-2; prm-151) in patients with IPF was discontinued because of failure to meet the primary endpoint.
        </p>
        <p class="headingAnchor" id="H4017008519">
         <span class="h2">
          Pamrevlumab (FG-3019)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pamrevlumab (FG-3019) is a fully humanized, monoclonal antibody specifically designed to target connective tissue growth factor, a central mediator in the pathogenesis of fibrosis [
         <a href="#rid188">
          188
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4300.html" rel="external">
          "Pathogenesis of idiopathic pulmonary fibrosis", section on 'Cytokines, growth factors, and other molecules'
         </a>
         .)
        </p>
        <p>
         In a phase 2 trial of 103 patients with IPF, patients receiving intravenous pamrevlumab (30 mg/kg every three weeks) had a smaller decline in FVC at 48 weeks compared with patients receiving placebo (-2.9 versus -7.2 percent) [
         <a href="#rid189">
          189
         </a>
         ]. A decline of greater than 10 percent in FVC or death was less frequent in the pamrevlumab group (10 versus 31 percent).
        </p>
        <p>
         The phase 3 ZEPHYRUS-1 and ZEPHYRUS-2 trials evaluating the safety and efficacy of pamrevlumab in patients with IPF were discontinued because of failure to meet both the primary endpoint of change from baseline in FVC at week 48 and the secondary endpoint of time to disease progression (FVC decline of ≥10 percent predicted or death).
        </p>
        <p class="headingAnchor" id="H1006092615">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118793.html" rel="external">
          "Society guideline links: Interstitial lung disease"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/122211.html" rel="external">
          "Society guideline links: Pulmonary rehabilitation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H97178226">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83031.html" rel="external">
          "Patient education: Idiopathic pulmonary fibrosis (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/130880.html" rel="external">
          "Patient education: Pulmonary rehabilitation (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H48">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Management of IPF generally includes a combination of supportive care, use of selected medications (eg,
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         ), consideration for participation in clinical trials, referral for lung transplant evaluation (when appropriate), and identification and treatment of comorbidities. (See
         <a class="local">
          'Our approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         – We offer supportive care (eg, supplemental oxygen, pulmonary rehabilitation, and COVID-19, pneumococcal, and seasonal influenza vaccination) and provide information about end-of-life issues and advanced directives to all patients. (See
         <a class="local">
          'General approach'
         </a>
         above and
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We use several preventive measures to reduce the risk of lung injury and consequent acute exacerbations of IPF. These include vaccination against respiratory viruses and infections, early treatment of bacterial or viral pulmonary infection, screening for and treatment of dysphagia and reflux aspiration, and avoidance of mechanical ventilation in elective procedures. (See
         <a class="local">
          'Prevention of pulmonary infections and acute exacerbations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Palliative measures (eg, facial cooling with a fan, opioids, anxiolytics) may be helpful for patients with refractory dyspnea or cough. Patients with advanced IPF may benefit from palliative care  (
         <a class="graphic graphic_table graphicRef87287" href="/z/d/graphic/87287.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef61282" href="/z/d/graphic/61282.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Palliative care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antifibrotic therapy
         </strong>
         – For patients with mild-to-moderate IPF based on pulmonary function tests who live in an area where either
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         or
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         is available, we recommend initiating therapy with the available agent (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Current data are insufficient to direct a firm choice between nintedanib and pirfenidone. Patient preference and tolerances should be considered, particularly regarding potential adverse effects. (See
         <a class="local">
          'Our approach'
         </a>
         above and
         <a class="local">
          'Assessing disease severity and prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The dose of
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         is 150 mg by mouth twice daily. Patients with known liver disease (Pugh B or worse) or full anticoagulation are not candidates for nintedanib. Diarrhea, nausea, vomiting, and liver function test elevation are common side effects of nintedanib. (See
         <a class="local">
          'Nintedanib'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The dose of
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         ranges up to 40 mg/kg per day (to maximum of 2403 mg per day) in three divided oral doses. Rash, photosensitivity, nausea, and abdominal discomfort are common side effects of pirfenidone. (See
         <a class="local">
          'Pirfenidone'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with more severe IPF, we also suggest therapy with either
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         or
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Based on observational data, nintedanib and pirfenidone appear to reduce lung function decline in patients with more advanced disease, like the effect in less advanced disease. The decision to try one of these medications depends on the values and preferences of the patient regarding a choice of active therapy with substantial adverse effects versus supportive care alone. (See
         <a class="local">
          'Role in more advanced disease'
         </a>
         above and
         <a class="local">
          'Role in more advanced disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Agents without benefit
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adjunctive therapies
         </strong>
         – Use of empiric antireflux medications, anticoagulants, or antibiotics for the improvement of pulmonary outcomes in patients with IPF is unlikely to be beneficial based on negative results from clinical trials. (See
         <a class="local">
          'Empiric treatment for asymptomatic gastroesophageal reflux'
         </a>
         above and
         <a class="local">
          'Anticoagulation'
         </a>
         above and
         <a class="local">
          'Maintenance antibiotic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immunosuppressants
         </strong>
         – Systemic glucocorticoid monotherapy, combination therapy with
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , and (N)
         <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">
          acetylcysteine
         </a>
         (NAC), monotherapy with NAC, and other broadly targeted immunosuppressants are no longer part of the routine maintenance care for patients with IPF, as there is no demonstrated efficacy, and they may be harmful. (See
         <a class="local">
          'Azathioprine, prednisone, and (N) acetylcysteine'
         </a>
         above and
         <a class="local">
          '(N) acetylcysteine'
         </a>
         above and
         <a class="local">
          'Other immunosuppressants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oral pulmonary vasodilators
         </strong>
         – Trials of endothelin receptor antagonists and phosphodiesterase-5 inhibitors failed to show an improvement in dyspnea or quality of life in multiple clinical trials. Although occasionally used for select patients with pulmonary hypertension otherwise out of proportion to the severity of their disease, these agents are not likely to benefit most patients with IPF. (See
         <a class="local">
          'Endothelin receptor antagonists'
         </a>
         above and
         <a class="local">
          'Phosphodiesterase-5 inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lung transplantation
         </strong>
         – Lung transplantation may be an option for patients with progressive disease and minimal comorbidities. For appropriate patients (based on criteria from the United Network for Organ Sharing [UNOS]), we suggest early referral for lung transplantation evaluation rather than waiting until the patient has developed advanced disease (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Lung transplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Participation in clinical trials
         </strong>
         – While antifibrotic agents slow disease progression, a therapeutic response is obtained in only a portion of patients, and survival is poor even for those who respond. A number of potential therapies are in various stages of development. Participation in clinical trials is an important way to improve the therapeutic options available for IPF. (See
         <a class="local">
          'Future directions'
         </a>
         above and
         <a class="local">
          'Clinical trials'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005; 172:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378:1949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192:e3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KR, Toews GB, Lynch JP 3rd, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright PH, Heard BE, Steel SJ, Turner-Warwick M. Cryptogenic fibrosing alveolitis: assessment by graded trephine lung biopsy histology compared with clinical, radiographic, and physiological features. Br J Dis Chest 1981; 75:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arakawa H, Honma K. Honeycomb lung: history and current concepts. AJR Am J Roentgenol 2011; 196:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009; 136:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mermigkis C, Bouloukaki I, Antoniou K, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath 2015; 19:385.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence (NICE). Diagnosis and management of suspected idiopathic pulmonary fibrosis, 2013. http://www.nice.org.uk/nicemedia/live/14183/64119/64119.pdf (Accessed on January 27, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryerson CJ, Arean PA, Berkeley J, et al. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology 2012; 17:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, et al. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest 2011; 139:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collard HR, Tino G, Noble PW, et al. Patient experiences with pulmonary fibrosis. Respir Med 2007; 101:1350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daniels CE, Ryu JH. Treatment of idiopathic pulmonary fibrosis. Semin Respir Crit Care Med 2006; 27:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreira A, Garvey C, Connors GL, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest 2009; 135:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008; 13:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salhi B, Troosters T, Behaegel M, et al. Effects of pulmonary rehabilitation in patients with restrictive lung diseases. Chest 2010; 137:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozu R, Senjyu H, Jenkins SC, et al. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration 2011; 81:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huppmann P, Sczepanski B, Boensch M, et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J 2013; 42:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson RM, Gómez-Marín OW, Ramos CF, et al. Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. Lung 2014; 192:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2014; :CD006322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vainshelboim B, Oliveira J, Yehoshua L, et al. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration 2014; 88:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nolan CM, Polgar O, Schofield SJ, et al. Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World Study. Chest 2022; 161:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao J, Metra B, George G, et al. Mortality among Patients with COVID-19 and Different Interstitial Lung Disease Subtypes: A Multicenter Cohort Study. Ann Am Thorac Soc 2022; 19:1435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcon A, Schievano E, Fedeli U. Mortality Associated with Idiopathic Pulmonary Fibrosis in Northeastern Italy, 2008-2020: A Multiple Cause of Death Analysis. Int J Environ Res Public Health 2021; 18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collard HR, Ryerson CJ, Corte TJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 2016; 194:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melgar M, Britton A, Roper LE, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghincea A, Ryu C, Herzog EL. An Acute Exacerbation of Idiopathic Pulmonary Fibrosis After BNT162b2 mRNA COVID-19 Vaccination: A Case Report. Chest 2022; 161:e71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bocchino M, Rea G, Buonocore A, et al. Combination of acute exacerbation of idiopathic nonspecific interstitial pneumonia and pulmonary embolism after booster anti-COVID-19 vaccination. Respir Med Case Rep 2022; 38:101674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bando T, Takei R, Mutoh Y, et al. Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination. Eur Respir J 2022; 59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sgalla G, Magrì T, Lerede M, et al. COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2022; 206:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee YH, Kim CH, Lee J. Coronavirus disease 2019 pneumonia may present as an acute exacerbation of idiopathic pulmonary fibrosis. J Thorac Dis 2020; 12:3902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Earl N, Schoeneberg D, Davidson PD. Severe progression of idiopathic pulmonary fibrosis post-COVID-19 infection. BMJ Case Rep 2021; 14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goto Y, Sakamoto K, Fukihara J, et al. COVID-19-Triggered Acute Exacerbation of IPF, an Underdiagnosed Clinical Entity With Two-Peaked Respiratory Failure: A Case Report and Literature Review. Front Med (Lausanne) 2022; 9:815924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alamer A, Jones R, Drinnan M, et al. Oropharyngeal swallowing physiology and safety in patients with Idiopathic Pulmonary Fibrosis: a consecutive descriptive case series. BMC Pulm Med 2022; 22:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, McLaughlin S, Collard HR. Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2011; 17:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer KC, Danoff SK, Lancaster LH, Nathan SD. Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key Questions. Chest 2015; 148:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang Z, Hoffman LA, Nouraie M, et al. Referral to Palliative Care Infrequent in Patients with Idiopathic Pulmonary Fibrosis Admitted to an Intensive Care Unit. J Palliat Med 2017; 20:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlos WG, Strek ME, Wang TS, et al. Treatment of Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc 2016; 13:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest 2021; 160:1751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canestaro WJ, Forrester SH, Raghu G, et al. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. Chest 2016; 149:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dempsey TM, Thao V, Helfinstine DA Jr, et al. Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis. Eur Respir J 2023; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao J, Fares J, George G, et al. Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis. Respirology 2023; 28:1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wuyts WA, Kolb M, Stowasser S, et al. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value. Lung 2016; 194:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harari S, Caminati A, Poletti V, et al. A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis. Respiration 2018; 95:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45:1434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laurenson S, Sidhu R, Goodall M, Adler AI. NICE guidance on nintedanib for treating idiopathic pulmonary fibrosis. Lancet Respir Med 2016; 4:176.
          </a>
         </li>
         <li class="breakAll">
          Nintedanib. US Food and Drug Administration (FDA) approved product information. US National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da1c9f37-779e-4682-816f-93d0faa4cfc9 (Accessed on November 10, 2014).
         </li>
         <li class="breakAll">
          Vargatef, INN-Nintedanib. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/product-information/vargatef-epar-product-information_en.pdf (Accessed on January 18, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galli JA, Pandya A, Vega-Olivo M, et al. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Respirology 2017; 22:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antoniou K, Markopoulou K, Tzouvelekis A, et al. Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. ERJ Open Res 2020; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cameli P, Refini RM, Bergantini L, et al. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study. Front Mol Biosci 2020; 7:581828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harari S, Pesci A, Albera C, et al. Nintedanib in IPF: Post hoc Analysis of the Italian FIBRONET Observational Study. Respiration 2022; 101:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costabel U, Inoue Y, Richeldi L, et al. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. Am J Respir Crit Care Med 2016; 193:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, Kreuter M, Selman M, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax 2018; 73:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med 2016; 113:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KR, Kolb M, Vancheri C, et al. Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. Eur Respir J 2018; 52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonella F, Kreuter M, Hagmeyer L, et al. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis. Respiration 2016; 92:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon HY, Park S, Kim DS, Song JW. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis. Respir Res 2018; 19:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunninghake GW, Kalica AR. Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007; 132:1311.
          </a>
         </li>
         <li class="breakAll">
          Pirfenidone. US Food and Drug Administration (FDA) revised label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208780s007,022535s016lbl.pdf (Accessed on March 07, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molina-Molina M, Shull JG, Vicens-Zygmunt V, et al. Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial. Eur Respir J 2023; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014; 19:740.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration (FDA).  Highlights of prescribing information for Esbriet (pirfenidone). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022535s012,208780s002lbl.pdf (Accessed on August 12, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Togami K, Kanehira Y, Tada H. Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis. Biol Pharm Bull 2013; 36:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011; 22:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999; 159:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377:1760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010; :CD003134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okuda R, Hagiwara E, Baba T, et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 2013; 107:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lederer DJ, Bradford WZ, Fagan EA, et al. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest 2015; 148:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016; 47:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 2016; 71:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med 2017; 5:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 2002; 76:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costabel U, Albera C, Glassberg MK, et al. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respir Res 2019; 20:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon HY, Kim DS, Song JW. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis. Respiration 2019; 97:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tzouvelekis A, Ntolios P, Karampitsakos T, et al. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study. Pulm Pharmacol Ther 2017; 46:48.
          </a>
         </li>
         <li class="breakAll">
          International Society for Heart and Lung Transplantation Registry. Adult Lung Transplantation Statistics: Kaplan-Meier Survival by Major Diagnosis. https://ishltregistries.org/registries/slides.asp (Accessed on July 21, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003; 126:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinman TI, Becker BN, Frost AE, et al. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001; 71:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan SD. POINT: Should Every Patient With Idiopathic Pulmonary Fibrosis Be Referred for Transplant Evaluation? Yes. Chest 2020; 157:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glanville AR. COUNTERPOINT: Should Every Patient With Idiopathic Pulmonary Fibrosis Be Referred for Transplant Evaluation? No. Chest 2020; 157:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer DM, Edwards LB, Torres F, et al. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg 2005; 79:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neurohr C, Huppmann P, Thum D, et al. Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis. Transpl Int 2010; 23:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ten Klooster L, Nossent GD, Kwakkel-van Erp JM, et al. Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation. Lung 2015; 193:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spratt JR, Tomic R, Brown RZ, et al. Single Versus Bilateral Lung Transplantation for Idiopathic Pulmonary Fibrosis in the Lung Allocation Score Era. J Surg Res 2019; 234:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitton TP, Kosowski TR, Barreiro CJ, et al. Impact of secondary pulmonary hypertension on lung transplant outcome. J Heart Lung Transplant 2005; 24:1254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008; 76:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Date H, Tanimoto Y, Goto K, et al. A new treatment strategy for advanced idiopathic interstitial pneumonia: living-donor lobar lung transplantation. Chest 2005; 128:1364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toronto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med 1986; 314:1140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Experience with single-lung transplantation for pulmonary fibrosis. The Toronto Lung Transplant Group. JAMA 1988; 259:2258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grossman RF, Frost A, Zamel N, et al. Results of single-lung transplantation for bilateral pulmonary fibrosis. The Toronto Lung Transplant Group. N Engl J Med 1990; 322:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyers BF, Lynch JP, Trulock EP, et al. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience. J Thorac Cardiovasc Surg 2000; 120:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyoshi S, Schaefers HJ, Trulock EP, et al. Donor selection for single and double lung transplantation. Chest size matching and other factors influencing posttransplantation vital capacity. Chest 1990; 98:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borie R, Kannengiesser C, Hirschi S, et al. Severe hematologic complications after lung transplantation in patients with telomerase complex mutations. J Heart Lung Transplant 2015; 34:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silhan LL, Shah PD, Chambers DC, et al. Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. Eur Respir J 2014; 44:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tokman S, Singer JP, Devine MS, et al. Clinical outcomes of lung transplant recipients with telomerase mutations. J Heart Lung Transplant 2015; 34:1318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brestoff JR, Vessoni AT, Brenner KA, et al. Acute graft-versus-host disease following lung transplantation in a patient with a novel TERT mutation. Thorax 2018; 73:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hannan SJ, Iasella CJ, Sutton RM, et al. Lung transplant recipients with telomere-mediated pulmonary fibrosis have increased risk for hematologic complications. Am J Transplant 2023; 23:1590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park SJ, Nguyen DQ, Savik K, et al. Pre-transplant corticosteroid use and outcome in lung transplantation. J Heart Lung Transplant 2001; 20:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schäfers HJ, Wagner TO, Demertzis S, et al. Preoperative corticosteroids. A contraindication to lung transplantation? Chest 1992; 102:1522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAnally KJ, Valentine VG, LaPlace SG, et al. Effect of pre-transplantation prednisone on survival after lung transplantation. J Heart Lung Transplant 2006; 25:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schachter LM, Dixon J, Pierce RJ, O'Brien P. Severe gastroesophageal reflux is associated with reduced carbon monoxide diffusing capacity. Chest 2003; 123:1932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, Collard HR, Raghu G, et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med 2010; 123:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pashinsky YY, Jaffin BW, Litle VR. Gastroesophageal reflux disease and idiopathic pulmonary fibrosis. Mt Sinai J Med 2009; 76:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bandeira CD, Rubin AS, Cardoso PF, et al. Prevalence of gastroesophageal reflux disease in patients with idiopathic pulmonary fibrosis. J Bras Pneumol 2009; 35:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Yang ST, Spada C, et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006; 129:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dutta P, Funston W, Mossop H, et al. Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis. Thorax 2019; 74:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds CJ, Del Greco M F, Allen RJ, et al. The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study. Eur Respir J 2023; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu J, Zhou D, Wang J, et al. A Causal Atlas on Comorbidities in Idiopathic Pulmonary Fibrosis: A Bidirectional Mendelian Randomization Study. Chest 2023; 164:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022; 205:e18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobin RW, Pope CE 2nd, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158:1804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sweet MP, Hoopes C, Golden J, et al. Prevalence of delayed gastric emptying and gastroesophageal reflux in patients with end-stage lung disease. Ann Thorac Surg 2006; 82:1570; author reply 1570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hershcovici T, Jha LK, Johnson T, et al. Systematic review: the relationship between interstitial lung diseases and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011; 34:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khor YH, Bissell B, Ghazipura M, et al. Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc 2022; 19:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Pellegrini CA, Yow E, et al. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respir Med 2018; 6:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:1390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008; 178:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sode BF, Dahl M, Nielsen SF, Nordestgaard BG. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med 2010; 181:1085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128:1475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinder BW, Collard HR, King TE Jr. Anticoagulant therapy and idiopathic pulmonary fibrosis. Chest 2006; 130:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2014; 2:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 190:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molyneaux PL, Willis-Owen SAG, Cox MJ, et al. Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2017; 195:1640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson AM, Clark AB, Cahn T, et al. Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial. JAMA 2020; 324:2282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez FJ, Yow E, Flaherty KR, et al. Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. JAMA 2021; 325:1841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantin AM, North SL, Fells GA, et al. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987; 79:1665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer A, Buhl R, Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994; 7:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer A, Buhl R, Kampf S, Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med 1995; 152:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997; 156:1897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behr J, Degenkolb B, Krombach F, Vogelmeier C. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur Respir J 2002; 19:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, DeAndrade J, Anstrom KJ, et al. A double blind, placebo-controlled, randomized trial of N-acetylcysteine in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 189:A6601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, de Andrade JA, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collard HR, Ryu JH, Douglas WW, et al. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004; 125:2169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas WW, Ryu JH, Bjoraker JA, et al. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin Proc 1997; 72:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000; 161:1172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 1998; 158:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selman M, Carrillo G, Salas J, et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998; 114:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, King TE Jr, Behr J, et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010; 35:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 2013; 42:1622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson RM, Glassberg MK, Ramos CF, et al. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung 2010; 188:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolb M, Raghu G, Wells AU, et al. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med 2018; 379:1722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behr J, Kolb M, Song JW, et al. Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). Am J Respir Crit Care Med 2019; 200:1505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang J, Song JW. Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis. Sci Rep 2021; 11:17824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cegla UH. [Treatment of idiopathic fibrosing alveolitis. Therapeutic experiences with azathioprine-prednisolone and D-penicillamine-prednisolone combination therapy]. Schweiz Med Wochenschr 1977; 107:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapela R, Zúñiga G, Selman M. D-penicillamine in the therapy of fibrotic lung diseases. Int J Clin Pharmacol Ther Toxicol 1986; 24:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Brown KK, Collard HR, et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med 2017; 5:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lota HK, Wells AU. The evolving pharmacotherapy of pulmonary fibrosis. Expert Opin Pharmacother 2013; 14:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selman M, Pardo A, Richeldi L, Cerri S. Emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs 2011; 16:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vancheri C, Kreuter M, Richeldi L, et al. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. Am J Respir Crit Care Med 2018; 197:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45:1382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KR, Fell CD, Huggins JT, et al. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Eur Respir J 2018; 52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hisata S, Bando M, Homma S, et al. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan. Respir Investig 2021; 59:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrmann FE, Hesslinger C, Wollin L, Nickolaus P. BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. Front Pharmacol 2022; 13:838449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, Azuma A, Cottin V, et al. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. N Engl J Med 2022; 386:2178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray LA, Chen Q, Kramer MS, et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol 2011; 43:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, van den Blink B, Hamblin MJ, et al. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. JAMA 2018; 319:2299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, van den Blink B, Hamblin MJ, et al. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respir Med 2019; 7:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Hamblin MJ, Brown AW, et al. Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study. Respir Res 2022; 23:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghu G, Scholand MB, de Andrade J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J 2016; 47:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richeldi L, Fernández Pérez ER, Costabel U, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2020; 8:25.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4328 Version 97.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15894598" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21471066" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21719092" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26177183" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11239846" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/634315" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Natural history and treated course of usual and desquamative interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7259967" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Cryptogenic fibrosing alveolitis: assessment by graded trephine lung biopsy histology compared with clinical, radiographic, and physiological features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15968010" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The clinical course of patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21427324" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Honeycomb lung: history and current concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12917227" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22586007" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A multidimensional index and staging system for idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19567497" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Obstructive sleep apnea is common in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25028171" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25028171" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22221976" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Depression is a common and chronic comorbidity in patients with interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20688924" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Depression and functional status are strongly associated with dyspnea in interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17107778" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Patient experiences with pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17195143" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Treatment of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18245143" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18849399" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18399862" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19858229" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Effects of pulmonary rehabilitation in patients with restrictive lung diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20516666" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23100507" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24705678" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25284270" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pulmonary rehabilitation for interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25341682" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34699771" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35499867" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Mortality among Patients with COVID-19 and Different Interstitial Lung Disease Subtypes: A Multicenter Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34299699" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Mortality Associated with Idiopathic Pulmonary Fibrosis in Northeastern Italy, 2008-2020: A Multiple Cause of Death Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27299520" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37471262" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35131075" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : An Acute Exacerbation of Idiopathic Pulmonary Fibrosis After BNT162b2 mRNA COVID-19 Vaccination: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35637916" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Combination of acute exacerbation of idiopathic nonspecific interstitial pneumonia and pulmonary embolism after booster anti-COVID-19 vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35144990" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35412453" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32802476" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Coronavirus disease 2019 pneumonia may present as an acute exacerbation of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34667037" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Severe progression of idiopathic pulmonary fibrosis post-COVID-19 infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35187001" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : COVID-19-Triggered Acute Exacerbation of IPF, an Underdiagnosed Clinical Entity With Two-Peaked Respiratory Failure: A Case Report and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36384569" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Oropharyngeal swallowing physiology and safety in patients with Idiopathic Pulmonary Fibrosis: a consecutive descriptive case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22607134" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22561965" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23648946" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21760508" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Comprehensive care of the patient with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26149553" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key Questions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27754815" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Referral to Palliative Care Infrequent in Patients with Idiopathic Pulmonary Fibrosis Admitted to an Intensive Care Unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26730865" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Treatment of Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34217681" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26836914" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37678948" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37534632" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27377558" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29587263" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25745043" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24836310" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26826906" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : NICE guidance on nintedanib for treating idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26826906" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : NICE guidance on nintedanib for treating idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26826906" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : NICE guidance on nintedanib for treating idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28317233" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32010718" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33102528" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35078170" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Nintedanib in IPF: Post hoc Analysis of the Italian FIBRONET Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21992121" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26393389" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28993537" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26915984" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29946007" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20007927" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27544537" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30340638" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7881692" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Approaches to the treatment of pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17934117" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Molecular targets in pulmonary fibrosis: the myofibroblast in focus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17934117" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Molecular targets in pulmonary fibrosis: the myofibroblast in focus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37857429" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24836849" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24836849" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24088250" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17702727" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21511828" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pirfenidone for diabetic nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10194146" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15665326" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19996196" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Pirfenidone in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21571362" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20824834" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Non-steroid agents for idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23849626" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25856121" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26647432" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24836312" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26968970" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27876247" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12126938" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28365056" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30866942" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30332670" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28843616" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28843616" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12928646" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11397947" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Guidelines for the referral and management of patients eligible for solid organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32505304" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : POINT: Should Every Patient With Idiopathic Pulmonary Fibrosis Be Referred for Transplant Evaluation? Yes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32505305" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : COUNTERPOINT: Should Every Patient With Idiopathic Pulmonary Fibrosis Be Referred for Transplant Evaluation? No.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25085497" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15734411" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20230541" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26404700" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30527505" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Single Versus Bilateral Lung Transplantation for Idiopathic Pulmonary Fibrosis in the Lung Allocation Score Era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16143242" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Impact of secondary pulmonary hypertension on lung transplant outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18216461" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16162730" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : A new treatment strategy for advanced idiopathic interstitial pneumonia: living-donor lobar lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3515192" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Unilateral lung transplantation for pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3280841" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Experience with single-lung transplantation for pulmonary fibrosis. The Toronto Lung Transplant Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2308601" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Results of single-lung transplantation for bilateral pulmonary fibrosis. The Toronto Lung Transplant Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10884661" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2376163" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Donor selection for single and double lung transplantation. Chest size matching and other factors influencing posttransplantation vital capacity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25612863" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Severe hematologic complications after lung transplantation in patients with telomerase complex mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24833766" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Lung transplantation in telomerase mutation carriers with pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26169663" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Clinical outcomes of lung transplant recipients with telomerase mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29382801" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Acute graft-versus-host disease following lung transplantation in a patient with a novel TERT mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37392813" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Lung transplant recipients with telomere-mediated pulmonary fibrosis have increased risk for hematologic complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11257556" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Pre-transplant corticosteroid use and outcome in lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1424876" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Preoperative corticosteroids. A contraindication to lung transplantation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16399533" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Effect of pre-transplantation prednisone on survival after lung transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12796170" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Severe gastroesophageal reflux is associated with reduced carbon monoxide diffusing capacity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20362747" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Does chronic microaspiration cause idiopathic pulmonary fibrosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19170215" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Gastroesophageal reflux disease and idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20126919" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Prevalence of gastroesophageal reflux disease in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16537884" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30610155" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37080571" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample Mendelian randomisation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36870387" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : A Causal Atlas on Comorbidities in Idiopathic Pulmonary Fibrosis: A Bidirectional Mendelian Randomization Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35486072" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9847271" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16387946" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16996990" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Prevalence of delayed gastric emptying and gastroesophageal reflux in patients with end-stage lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21999527" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Systematic review: the relationship between interstitial lung diseases and gastro-oesophageal reflux disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35486080" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30100404" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21700909" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18755924" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20167844" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16162746" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Anticoagulant therapy for idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16738197" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Current perspectives on the treatment of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16840421" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Anticoagulant therapy and idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24767767" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25184687" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28085486" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33289822" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33974018" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16306520" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : High-dose acetylcysteine in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3034979" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8013597" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7663783" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9412572" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12030732" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2913886" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : A double blind, placebo-controlled, randomized trial of N-acetylcysteine in idiopathic pulmonary fibrosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24836309" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15189938" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18669816" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9070193" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Colchicine versus prednisone as treatment of usual interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10764308" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9655733" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9726738" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19570573" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17901413" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19679600" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21474646" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23682110" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20012639" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20484178" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30220235" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31365829" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34497295" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/834991" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : [Treatment of idiopathic fibrosing alveolitis. Therapeutic experiences with azathioprine-prednisolone and D-penicillamine-prednisolone combination therapy].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3957484" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : D-penicillamine in the therapy of fibrotic lung diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27939076" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23265249" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : The evolving pharmacotherapy of pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21410428" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Emerging drugs for idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28889759" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25504994" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29946005" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33994347" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35517783" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35569036" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21044893" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29800034" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31122893" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35597980" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26965296" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31575509" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
